PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-1.55%
Negative revenue growth while MRVL stands at 7.04%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
3.51%
Gross profit growth under 50% of MRVL's 9.12%. Michael Burry would be concerned about a severe competitive disadvantage.
5.06%
EBIT growth below 50% of MRVL's 20.91%. Michael Burry would suspect deeper competitive or cost structure issues.
5.06%
Operating income growth under 50% of MRVL's 20.91%. Michael Burry would be concerned about deeper cost or sales issues.
16.13%
Net income growth at 50-75% of MRVL's 21.67%. Martin Whitman would question fundamental disadvantages in expenses or demand.
15.63%
EPS growth similar to MRVL's 16.67%. Walter Schloss would assume both have parallel share structures and profit trends.
10.00%
Diluted EPS growth under 50% of MRVL's 30.00%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.18%
Share reduction more than 1.5x MRVL's 0.76%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.19%
Diluted share reduction more than 1.5x MRVL's 0.76%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-47.14%
Negative OCF growth while MRVL is at 62.73%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-76.13%
Negative FCF growth while MRVL is at 83.50%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
386.85%
Similar 10Y revenue/share CAGR to MRVL's 374.41%. Walter Schloss might see both firms benefiting from the same long-term demand.
416.09%
5Y revenue/share CAGR 1.25-1.5x MRVL's 374.41%. Bruce Berkowitz would verify if cost efficiency or pricing power supports this advantage.
21.27%
3Y revenue/share CAGR under 50% of MRVL's 176.11%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
1047.86%
10Y OCF/share CAGR at 50-75% of MRVL's 1571.84%. Martin Whitman might fear a structural deficiency in operational efficiency.
200.98%
Below 50% of MRVL's 1571.84%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
6289.46%
3Y OCF/share CAGR 1.25-1.5x MRVL's 4458.54%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
637.92%
Below 50% of MRVL's 4742.96%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
408.37%
Below 50% of MRVL's 4742.96%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
1184.03%
3Y net income/share CAGR 1.25-1.5x MRVL's 801.58%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
921.18%
10Y equity/share CAGR 1.25-1.5x MRVL's 679.61%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
846.67%
5Y equity/share CAGR 1.25-1.5x MRVL's 679.61%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
30.11%
3Y equity/share CAGR above 1.5x MRVL's 15.55%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
39.23%
AR growth well above MRVL's 2.47%. Michael Burry fears inflated revenue or higher default risk in the near future.
-2.21%
Inventory is declining while MRVL stands at 0.85%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
5.70%
Asset growth 1.25-1.5x MRVL's 5.12%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
3.45%
Similar to MRVL's 3.44%. Walter Schloss finds parallel capital usage or profit distribution strategies.
-100.00%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-0.12%
Our R&D shrinks while MRVL invests at 1.76%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
7.54%
SG&A growth well above MRVL's 6.81%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.